Agenus (AGEN) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)

Agenus (AGEN) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 18.47%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.08%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 92.37%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Agenus 234.10 Mn 199.10 Mn 33.74 Mn 254.71%

Historic Data

Download Data
DateValue
Mar 31, 2026 254.71%
Dec 31, 2025 76.84%
Sep 30, 2025 196.12%
Jun 30, 2025 47.29%
Mar 31, 2025 59.12%
Dec 31, 2024 0.93%
Sep 30, 2024 -6.72%
Jun 30, 2024 23.07%
Mar 31, 2024 9.32%
Dec 31, 2023 34.86%
Sep 30, 2023 -14.70%
Jun 30, 2023 -48.58%
Mar 31, 2023 -41.19%
Dec 31, 2022 -8.51%
Sep 30, 2022 -130.41%
Jun 30, 2022 44.22%
Mar 31, 2022 9.96%
Dec 31, 2021 -74.09%
Sep 30, 2021 448.60%
Jun 30, 2021 -75.34%